B
BMRN
BMRNUnverified10 segments tracked|6 years of data|Annual (10-K)
Total Revenue
$5.5B126.5%
FY2024
Operating Segments
10Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%Products Excluding ALDURAZYME
Segment Shift
Products Excluding ALDURAZYME has grown from 0.0% to 47.9% of total revenue since FY2019, with 0.0% operating margins. Meanwhile, ROCTAVIAN is the fastest growing at +647.1% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| Products Excluding ALDURAZYME | $2.6B | $0 | 0.0% | 47.9% | +0.0% |
| VIMIZIM | $740M | $0 | 0.0% | 13.5% | +5.5% |
| VOXZOGO | $735M | $0 | 0.0% | 13.4% | +56.4% |
| NAGLAZYME | $480M | $0 | 0.0% | 8.8% | +14.1% |
| PALYNZIQ | $355M | $0 | 0.0% | 6.5% | +16.8% |
| ALDURAZYME | $184M | $0 | 0.0% | 3.4% | +40.1% |
| BRINEURA | $169M | $0 | 0.0% | 3.1% | +4.4% |
| KUVAN | $121M | $0 | 0.0% | 2.2% | -33.1% |
| Royalty And Other | $44M | $0 | 0.0% | 0.8% | -4.8% |
| ROCTAVIAN | $26M | $0 | 0.0% | 0.5% | +647.1% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free